Komori
Governance4512WAKAMOTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Corporate Governance Report 2024/05/15

The Company is structured as a company with an Audit and Supervisory Committee. The report presents the composition of the Board of Directors and the skills matrix for each director. Specific changes from the previous report cannot be confirmed from the body of the report.

Worth reading
80Important
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Avoiding a definitive answer
How definitive the wording is.

Governance structure

Company with an Audit and Supervisory Committee
Number of directors7 (including 3 outside directors)
Number of independent officers3Number

This is the number of people reported to the exchange as independent officers. Whether someone is an outside officer and whether they qualify as independent are separate determinations.

Committee4
指名報酬委員会Audit and Supervisory Committeeリスク管理委員会コンプライアンス委員会
Governance structure
ItemDetails
Corporate Governance StructureCompany with an Audit and Supervisory Committee
Number of directors7 (including 3 outside directors)
Number of independent officers3
Committee指名報酬委員会(社外委員の割合はNot disclosed)、監査等委員会(社外委員の割合はNot disclosed)、リスク管理委員会、コンプライアンス委員会
Items this document does not state (4)
Policy on cross-shareholdingsTakeover defensesControlling shareholderChanges this time

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

No reason for the change is stated.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Corporate Governance Report 2024/05/15 | WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512) timely disclosure | Komori